Luxcel Biosciences Ltd Announce Further EU H2020 Success with €1.5million Award  and Rapid Expansion Plans

Luxcel Biosciences Ltd is delighted to announce a further European H2020 funding award, supporting the €1.5million MetaTox-HS product development, under the highly prestigious SME Instrument (SMEInst-02-2016-2017).  Drug failure and high development cost (est. €2.3bn/new drug) has driven enormous growth in market need for in vitro scientific tests and models of disease that better replicate drug effect in the patient (in vivo). Critical tests are either not available, or only available on a few large, expensive dedicated instruments. Luxcel Biosciences Ltd can now bring these high performance tests, to all laboratory scientists, for use on fluorescence microplate readers; the current laboratory standard instrument available in approximately 20,000 labs, without the need for new capital expenditure on instrumentation or software. Luxcel Biosciences’ low cost, flexible and easy to use in vitro cell metabolism and toxicity test kits and consumable products, developed and launched through MetaTox-HS (MitoXpress® UHS and dOxyCheck®) are made possible through an innovative synergy of fluorescence-based nanosensor technology and advanced polymer microfabrication.

“This award, following so quickly on the heels of a €2.5 million H2020 Fast Track to Innovation award announced in February 2017 (MetaCellTM), underpins our rapid expansion and brand leadership. Our growing portfolio of accessible and easy to use in vitro cell based assays means that we are truly becoming the one-stop-shop for Cell Metabolism whether you are an academic, a CRO or a Global Pharma company working in Drug Discovery” said Dr. Ian Hayes, Commercial & Operations Director, Luxcel Biosciences Ltd.

Leave a Comment